Abstract
Stem cell therapy (SCT) is a promising and prospective approach in the treatment of patients with severe peripheral arterial disorders, primarily with Buerger’s disease. However, very little is known about the duration of the effect of SCT, and to our best knowledge no data are available on the efficacy and safety of repeated SCT in patients with Buerger’s disease. Here we report on two patients with severe Buerger’s disease, who received repeated autologous bone marrow-derived stem cell therapy. Our results show that a second SCT, applied to a previously treated leg 30 or 36 months after the first treatment was efficient in both cases. After twelve months, the clinical state of the repeatedly treated lower limb improved spectacularly and non-healing ulcers healed more rapidly than after the first SCT. No severe adverse events were detected. Thus repeated SCT offers a safe and efficient treatment option for relapsing patients at the advanced stage of Buerger’s disease.
Highlights
Recent publications have proved the efficacy and safety of stem cell therapy (SCT) in patients with severePresented at the 54th Annual Meeting of German Society of Thrombosis Haemostasis (GTH), Nuremberg, February 2010
We report on two cases, where the lower limb of patients with Buerger’s disease, previously treated by autologous bone marrow-derived stem cell therapy (ABMSCT) [9], have been re-treated with freshly isolated autologous bone marrow derived isolated CD34+ cells
Both patients relapsed at 30 - 36 months after the first ABMSCT
Summary
Recent publications have proved the efficacy and safety of stem cell therapy (SCT) in patients with severePresented at the 54th Annual Meeting of German Society of Thrombosis Haemostasis (GTH), Nuremberg, February 2010. Recent publications have proved the efficacy and safety of stem cell therapy (SCT) in patients with severe. We report on two cases, where the lower limb of patients with Buerger’s disease, previously treated by autologous bone marrow-derived stem cell therapy (ABMSCT) [9], have been re-treated with freshly isolated autologous bone marrow derived isolated CD34+ cells. Both patients relapsed at 30 - 36 months after the first ABMSCT. As they responded to the first treatment, we decided to repeat ABMSCT with freshly isolated bone marrow derived CD34+ cells by using the same method as described in our previous publication [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
